Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
An RX mirror and its underlying label are not independent clinical confirmations.
Check source scope before reading a dose
ZELBORAF: baseline renal function and renal-toxicity monitoring
Product / population
Adult oral ZELBORAF for its labeled oncology indications; this is not a complete oncology regimen.
Renal method
Mild/moderate/severe renal categories; CrCl in mL/min in the supporting PK analysis
Source revision
07/2026
Retrieved
2026-11-07
Local review status
Selected named sections summarized; not a complete monograph or independent clinician approval.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
Renal category guidance is not severe-impairment or dialysis validation
The label and its mirror describe the same category-based limitation. The mirror is not a second independent clinical recommendation.
What to reconcile: Use the exact label and monitor kidney toxicity; seek specialist guidance for severe impairment or dialysis.
DailyMed / product prescribing information · Adult oral ZELBORAF for its labeled oncology indications; this is not a complete oncology regimen.
Renal method: Mild/moderate/severe renal categories; CrCl in mL/min in the supporting PK analysis Source date: 07/2026 Retrieved: 2026-11-07
Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.
Before using this finding
No HD or CRRT regimen established in these passages.
Dialysis evidence: No dialysis regimen established in selected content
Selected named sections summarized; not a complete monograph or independent clinician approval.
Sections 8.7, 12.3 and 5.11
Sections 8.7, 12.3 and 5.11
Situation
Source-specific guidance
Mild or moderate impairment
No renal dose adjustment recommended.
Severe impairment
Appropriate dose not established.
Renal toxicity
Creatinine before treatment and periodically.
Read the retained text before reformatting
Population pharmacokinetics support no dose adjustment for mild or moderate impairment. There was no formal renal-impairment study; the appropriate dose in severe impairment is not established. Renal failure, including interstitial nephritis and tubular necrosis, has been reported. Check serum creatinine before treatment and periodically. These passages do not establish a hemodialysis or CRRT regimen.
RDM71-vemurafenib-zelboraf-label-1 · Source locator: Sections 8.7, 12.3 and 5.11
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh Renal Dosing Master v7.4. Review the retrieval and revision dates attached to each source. Selecting a reference does not imply clinical verification.
